A patent review of P2X7 receptor antagonists to treat inflammatory diseases (2018-present)
文献类型：期刊论文
| 作者 | Iqbal, Jamshed1,2; Bano, Sehrish2; Khan, Imtiaz Ali2; Huang, Qing1 |
| 刊名 | EXPERT OPINION ON THERAPEUTIC PATENTS
 |
| 出版日期 | 2024-04-02 |
| 卷号 | 34 |
| 关键词 | drug discovery inflammation heterocyclic compounds calcium flux assay |
| ISSN号 | 1354-3776 |
| DOI | 10.1080/13543776.2024.2363885 |
| 通讯作者 | Iqbal, Jamshed(drjamshed@cuiatd.edu.pk) |
| 英文摘要 | IntroductionThe purinergic P2X7 receptor (P2X7R) is expressed on the surface of many different types of cells, including immune cells. Targeting P2X7R with antagonists has been studied for its potential therapeutic effects in a variety of inflammatory illnesses.Area CoveredMany chemical substances, including carboxamides, benzamides and nitrogen containing heterocyclic derivatives have demonstrated promising inhibitory potential for P2X7 receptor. The chemistry and clinical applications of P2X7R antagonists patented from 2018- present are discussed in this review.Expert OpinionPurinergic receptor inhibitor discovery and application has demonstrated the potential for therapeutic intervention, as demonstrated by pharmacological research. Few chemical modalities have been authorized for use in clinical settings, despite the fact that breakthroughs in crystallography and chemical biology have increased the knowledge of purinergic signaling and its consequences in disease. The many research projects and pharmaceutical movements that sustain dynamic P2X receptor programs over decades are evidence of the therapeutic values and academic persistence in purinergic study. P2X7R is an intriguing therapeutic target and possible biomarker for inflammation. Although several companies like Merck and AstraZeneca have published patents on P2X3 antagonists, the search for P2X7R antagonists has not stopped. Numerous pharmaceutical companies have disclosed different scaffolds, and some molecules are presently being studied in clinical studies. |
| WOS关键词 | ION-CHANNEL ; PHOSPHOLIPASE-D ; ATP ; ACTIVATION ; MECHANISMS ; MEMBRANE |
| 资助项目 | CAS President's International Fellowship Initiative (PIFI) project |
| WOS研究方向 | Pharmacology & Pharmacy |
| 语种 | 英语 |
| WOS记录号 | WOS:001243827100001 |
| 出版者 | TAYLOR & FRANCIS LTD |
| 资助机构 | CAS President's International Fellowship Initiative (PIFI) project |
| 源URL | [http://ir.hfcas.ac.cn:8080/handle/334002/136176]  |
| 专题 | 中国科学院合肥物质科学研究院 |
| 通讯作者 | Iqbal, Jamshed |
| 作者单位 | 1.Chinese Acad Sci, Inst Intelligent Machines, Hefei Inst Phys Sci, Hefei 230031, Peoples R China 2.COMSATS Univ Islamabad, Ctr Adv Drug Res, Abbottabad, Pakistan |
| 推荐引用方式 GB/T 7714 | Iqbal, Jamshed,Bano, Sehrish,Khan, Imtiaz Ali,et al. A patent review of P2X7 receptor antagonists to treat inflammatory diseases (2018-present)[J]. EXPERT OPINION ON THERAPEUTIC PATENTS,2024,34. |
| APA | Iqbal, Jamshed,Bano, Sehrish,Khan, Imtiaz Ali,&Huang, Qing.(2024).A patent review of P2X7 receptor antagonists to treat inflammatory diseases (2018-present).EXPERT OPINION ON THERAPEUTIC PATENTS,34. |
| MLA | Iqbal, Jamshed,et al."A patent review of P2X7 receptor antagonists to treat inflammatory diseases (2018-present)".EXPERT OPINION ON THERAPEUTIC PATENTS 34(2024). |
入库方式： OAI收割
来源：合肥物质科学研究院
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。